Page last updated: 2024-12-06
rutamarin
Description
Rutamarin is a coumarin derivative isolated from Ruta graveolens, a plant commonly known as rue. It has demonstrated various pharmacological activities, including anti-inflammatory, antioxidant, and antimicrobial properties. Rutamarin is synthesized through a multi-step process involving the reaction of umbelliferone with 3-methylbut-2-en-1-ol in the presence of a catalyst. Its importance lies in its potential therapeutic applications, particularly in treating inflammatory conditions and infections. The anti-inflammatory effects of rutamarin are attributed to its ability to inhibit the production of pro-inflammatory mediators, such as prostaglandins and leukotrienes. Research on rutamarin focuses on exploring its pharmacological profile, including its mechanism of action, efficacy, and safety in different model systems.'
rutamarin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 26948 |
CHEMBL ID | 1917738 |
CHEBI ID | 196315 |
SCHEMBL ID | 3414299 |
MeSH ID | M0079473 |
Synonyms (30)
Synonym |
nsc-263654 |
nsc263654 |
ccris 4345 |
2-(1-(acetyloxy)-1-methylethyl)-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro-7h-furo(3,2-g)(1)benzopyran-7-one |
brn 1400300 |
7h-furo(3,2-g)(1)benzopyran-7-one, 2,3-dihydro-6-(1,1-dimethylallyl)-2-(1-hydroxy-1-methylethyl)-, acetate |
2-(1-acetyloxy-1-methylethyl)-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro-7h-furo(3,2-g)(1)benzopyran-7-one |
nsc 263654 |
7h-furo(3,2-g)(1)benzopyran-7-one, 2-(1-(acetyloxy)-1-methylethyl)-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro- |
14882-94-1 |
rutamarin |
2-[6-(2-methylbut-3-en-2-yl)-7-oxo-2,3-dihydrofuro[3,2-g]chromen-2-yl]propan-2-yl acetate |
CHEBI:196315 |
2-[6-(2-methylbut-3-en-2-yl)-7-oxo-2,3-dihydrouro[3,2-g]chromen-2-yl]propan-2-yl acetate |
chalepin acetate |
1092383-76-0 |
5-19-06-00053 (beilstein handbook reference) |
CHEMBL1917738 |
SCHEMBL3414299 |
AWMHMGFGCLBSAY-UHFFFAOYSA-N |
unii-2ukd4797wg |
2-(1-(acetyloxy)-1-methylethyl)-6-(1,1-dimethyl-2-propen-1-yl)-2,3-dihydro-7h-furo(3,2-g)(1)benzopyran-7-one |
2ukd4797wg , |
rutamarin, (+/-)- |
(+/-)-rutamarin |
7h-furo(3,2-g)(1)benzopyran-7-one, 2-(1-(acetyloxy)-1-methylethyl)-6-(1,1-dimethyl-2-propen-1-yl)-2,3-dihydro- |
2-[6-(2-methylbut-3-en-2-yl)-7-oxo-2h,3h,7h-furo[3,2-g]chromen-2-yl]propan-2-yl acetate |
2-(6-(2-methylbut-3-en-2-yl)-7-oxo-2,3-dihydro-7h-furo[3,2-g]chromen-2-yl)propan-2-yl acetate |
Q27255620 |
DTXSID501030750 |
Drug Classes (1)
Class | Description |
psoralens | A furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 24.31 (24.57) | Research Supply Index | 2.48 (2.92) | Research Growth Index | 5.16 (4.65) | Search Engine Demand Index | 23.28 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |